Table 3 Night blood pressure fall (NBPF), morning surge (MS) and smoothness index (SI) after injection of liraglutide and placebo in the patients with eGFR < 30 ml/min and > 60 ml/min.

From: The impact of GLP-1 receptor agonist liraglutide on blood pressure profile, hydration, natriuresis in diabetic patients with severely impaired kidney function

eGFR < 30 ml/min/1.73mb

eGFR > 60 ml/min/1.73mb

 

Placebo

Liraglutide

p-value

 

Placebo

Liraglutide

p-value

NBPFa (%)

4.7 ± 8.3

3.6 ± 8

p = 0.81

NBPFa (%)

6.4 ± 9.2

7.3 ± 7.8

p = 0.63

MSa

(mmHg)

9.3 ± 17.1

15.7 ± 9.3

p = 0.15

MSa

(mmHg)

22.6 ± 14.3

15 ± 14.5

p = 0.04

ADIb

16.3

(13.9–17.4)

15.1

(11.2–18.2)

p = 0.41

ADI2

16.8

(14.1–19.2)

16.2

(13–18.5)

p = 0.65

  1. NBPF, night blood pressure fall; MS, morning surge; ADI, average deviation index.
  2. aMean ± standard deviation.
  3. bMedian with interquartile range (IQR).
  4. Significant values are in bold.
Back to article page